Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment

On:

Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.

Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.

Full results from the study are expected to be presented in 2023.

ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.

Source: Read Full Article

Lates News:
  1. BMW Thailand To Use Blockchain Technology For Daily Operations
  2. Bowlero Corp. Slips 8% Following Q1 Results
  3. Whale Moves 2,910 Bitcoin (BTC) To Exchange Amid FBI Warnings, A Bearish Signal?
  4. The DRC-20 Effect: How Dogecoin Tokens Outpaced Bitcoin’s Daily Transactions
  5. Bitcoin's $28,000 Hurdle Sparks Red Monday for Cryptocurrencies